trabectedin + olaparib
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma, Bone Tumor
Trial Timeline
Jul 20, 2014 → Dec 1, 2019
NCT ID
NCT02398058About trabectedin + olaparib
trabectedin + olaparib is a phase 1 stage product being developed by AstraZeneca for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02398058. Target conditions include Soft Tissue Sarcoma, Bone Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02398058 | Phase 1 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma